Related Experiment Video
Updated: Jun 9, 2026
08:02
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Model
Sayeda Yasmin-Karim1, Geraud Richards1, Gerassimos Mike Makrigiorgos1
1Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Advances in Radiation Oncology
|June 8, 2026
Summary
Linebacker-1 (LB1), a myricetin derivative, shows anticancer effects and enhances radiation therapy in lung cancer models. Combining LB1 with anti-PD1 immunotherapy further improves survival, suggesting its potential as a clinical radiosensitizer.
Area of Science:
- Oncology
- Drug Discovery
- Radiotherapy
Background:
- Myricetin, a dietary supplement, exhibits anticancer properties.
- Linebacker-1 (LB1) is a novel myricetin derivative with DNA-binding capabilities.
- LB1 shows potential as an antitumor agent.
Purpose of the Study:
- To evaluate the anticancer effect of LB1 in lung cancer.
- To assess the radiosensitizing potential of LB1.
- To investigate LB1's efficacy in combination with immunotherapy.
Main Methods:
- In vitro studies using human lung (A549) and colon (HT29) cancer cell lines.
- In vivo studies using a murine Lewis lung carcinoma (LLC1) model.
- Image-guided radiation therapy (IGRT) and combination therapy with anti-PD1 checkpoint inhibitors.
Main Results:
- LB1 demonstrated significant antineoplastic effects in vitro.
- IGRT significantly reduced tumor volume and increased survival in the murine model.
- Combination of LB1 with IGRT and/or anti-PD1 further enhanced survival rates without adverse effects.
Conclusions:
- LB1 exhibits anticancer and radiosensitizing effects in lung cancer models.
- Combination therapy with LB1, radiation, and anti-PD1 immunotherapy shows promising results.
- Further preclinical studies in orthotopic models are warranted for clinical translation.
